Connective tissue diseases: Translating the effects of BAFF in SLE.
Marston
Beth
B
Allergy/Immunology and Rheumatology Division, Department of Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA.
Looney
R John
RJ
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015551:Autoimmunity; D053264:B-Cell Activating Factor / Q000037:antagonists & inhibitors* / Q000276:immunology; D017326:Clinical Trials, Phase III as Topic; D004195:Disease Models, Animal; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D051379:Mice; D008822:Mice, Transgenic
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053264:B-Cell Activating Factor; D007166:Immunosuppressive Agents; C505719:TNFSF13B protein, human; C511911:belimumab
Arthritis Rheum. 2009 Sep 15;61(9):1168-78
19714604
Eur J Immunol. 2004 Oct;34(10):2750-9
15368291
Immunol Rev. 2008 Jun;223:156-74
18613835
J Immunol. 2008 Jun 1;180(11):7394-403
18490739
Arthritis Rheum. 2010 Aug;62(8):2432-42
20506216
Arthritis Rheum. 2010 Jan;62(1):201-10
20039404
J Exp Med. 1999 Dec 6;190(11):1697-710
10587360
Arthritis Rheum. 2005 Jul;52(7):2080-91
15986357
Blood. 2006 Oct 15;108(8):2687-94
16825497